Information contained on this page is provided by an independent third-party content provider. Frankly and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact [email protected]
SOURCE Research and Markets
DUBLIN, Nov 9, 2018 /PRNewswire/ —
The “Lennox Gastaut Syndrome – Market Insights, Epidemiology and Market Forecast-2027” drug pipelines has been added to ResearchAndMarkets.com’s offering.
Lennox Gastaut Syndrome – Market Insights, Epidemiology and Market Forecast-2027′ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Lennox Gastaut Syndrome in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Lennox Gastaut Syndrome from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
Lennox Gastaut Syndrome – Disease Understanding and Treatment Algorithm
The Lennox Gastaut Syndrome market report gives the thorough understanding of the Lennox Gastaut Syndrome by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Lennox Gastaut Syndrome in the US, Europe, and Japan.
Lennox Gastaut Syndrome Epidemiology
The Lennox Gastaut Syndrome epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed and treatable patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report is segmented by gender- specific [Male and Female] and seizure specific [Tonic, Myoclonic, Absence, Static, Partial].
According to this research, the prevalent cases of Lennox Gastaut Syndrome was 68,562 in 2016 in 7 MM and, is expected to increase during the study period i.e., 2016-2027. Among 7MM, United States account for highest prevalent cases of Lennox Gastaut Syndrome with 31,772 prevalent cases in 2016. In 7MM, males had highest prevalent cases of LGS as compared to females in 2016. This trend is expected to increase during the study period
Lennox Gastaut Syndrome Drug Chapters
This segment of the Lennox Gastaut Syndrome report encloses the detailed analysis of marketed drugs and late stage (Phase-III) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Currently, there are 7 drugs approved in market for Lennox Gastaut Syndrome along with other off-label therapies. This report includes detailed chapters of marketed along with the promising upcoming therapies.
Lennox Gastaut Syndrome Market Outlook
The Lennox Gastaut Syndrome market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
Lennox Gastaut Syndrome market is expected to grow during the forecasted period of 2018-2027 owing to the launch of three drugs (presently in Phase III and Phase II). Lennox Gastaut Syndrome Therapeutics market has seen a 7MM sales of USD 1356.4 million in 2016. The approved medications are Epidiolex (GW PHarma), Topamax (Jansenn Pharmaceuticals), Banzel (Jansenn Pharmaceuticals) , Lamictal (GlaxoSmithKline), Felbatol (Meda Pharmaceuticals), Onfi (Lundbeck) and Klonopin (Roche)
Lennox Gastaut Syndrome Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Lennox Gastaut Syndrome Report Insights
- Patient Population
- Therapeutic Approaches
- Pipeline Analysis
- Market Size and Trends
- Market Opportunities
- Impact of upcoming Therapies
Lennox Gastaut Syndrome Report Key Strengths
- 10 Year Forecast
- 7MM Coverage
- Epidemiology Segmentation
- Drugs Uptake
- Highly Analyzed Market
- Key Cross Competition
Lennox Gastaut Syndrome Report Assessment
- Current Treatment Practices
- Unmet Needs
- Detailed Pipeline Product Profiles
- Market Attractiveness
- Market Drivers and Barriers
- This report will help to develop Business Strategies by understanding the trends shaping and driving the Lennox Gastaut Syndrome market
- Organize sales and marketing efforts by identifying the best opportunities for Lennox Gastaut Syndrome market
- To understand the future market competition in the Lennox Gastaut Syndrome market.
Felbatol: Meda Pharmaceuticals
Epidiolex: Greenwich Biosciences
Banzel: Janssen Pharmaceuticals
Topamax: Janssen Pharmaceuticals
- Fycompa: Eisai
- ZX 008: Zogenix International Limited, Inc., a subsidiary of Zogenix
- TAK-935/ OV935: Takeda/Ovid
- Meda Pharmaceuticals
- Greenwich Biosciences
- Janssen Pharmaceuticals
- Zogenix International Limited, Inc., a subsidiary of Zogenix
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/x7ts2z/lennox_gastaut?w=5
Did you know that we also offer Custom Research? Visit our Custom Research page to learn more and schedule a meeting with our Custom Research Manager.
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
View original content:http://www.prnewswire.com/news-releases/lennox-gastaut-syndrome-insights-epidemiology-and-market-forecast-2016-2027-featuring-gsk-meds-pharma-roche-lundbeck-janssen-pharma-eisai-zogenix-international–takeda-300747459.html
©2017 PR Newswire. All Rights Reserved.